Page 4 - Biocon Pharma News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stocks in the news, big brokerage calls of the day, complete trade setup and much more!

The product is indicated for the prophylaxis of organ rejection in adult patients receiving a kidney transplant and is available in 180 mg and 360 mg strengths.

Biotechnology major Biocon on Thursday said its unit has received approval from the US health regulator to market a generic product. Biocon Pharma, a subsidiary of the company, has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Mycophenolic Acid, the company said in a regulatory filing. The product is

Health your username 8 hours ago On Friday, Celgene Corporation filed a complaint in the District of New Jersey. The case was filed against Biocon Pharma Inc. The action focuses on potential patent infringement regarding ten patents held by Celgene which would potentially be infringed upon by a potential generic drug created by Biocon. The patents address methods for treating cancer, specifically multiple myeloma and related blood and bone marrow cancers. The patents resulted in a drug regimen specifically designed to treat these patients after bone marrow transplantation, under the name Rev...

Biocon Pharma Limited receives GMP compliance certificate from MHRA, UK Posted On: 2021-04-11 20:08:53 (Time Zone: Arizona, USA) Biocon Pharma Limited, a wholly owned subsidiary of Biocon Limited, has received a certificate of Good Manufacturing Practice (GMP) compliance from the Medicines & Healthcare products Regulatory Agency (MHRA), the United Kingdom (UK), for its manufacturing facility at Biocon Park in Bengaluru. The certificate, which includes manufacturing and packaging of tablets and capsules in the non-potent and potent blocks of the facility, was issued based on a remote insp...